



Advanced
Training Course in
Kidney Transplantation

20²⁵
26

KIDNEY TRANSPLANT UNIT (KTU)

Vall d'Hebron University Hospital

VALL D'HEBRON UNIVERSITY HOSPITAL	5
1.1 The hospital in figures	6
1.2 Reference center in tertiary care and high complexity	6
1.2.1 Certifications and accreditations	7
1.3 Teaching	9
1.4 Research	10

2

PROCEDURES AND CONDITIONS	18
3.1 General course data	19
3.2 Registration procedures	19
3.3 Program approval	20
3.4 Requirements for staying at the centre	20
3.4.1 Relationship of professionals with the University Hospital Vall d'Hebron	20
3.4.2 Activities	20
3.5 Admission process at the centre	21
3.6 Cancellation of Training Program	21
3.7 Certification	21

4

1

ADVANCED TRAINING PROGRAM	11
2.1 Presentation	12
2.2 Justification	14
2.3 Course program	14
2.3.1 Course syllabus	14
2.3.2 Course objectives	15
2.3.3 Competencies to achieve	15
2.3.4 Teaching methodology	16
2.3.5 Evaluation	16
2.4 Management and teaching staff	17

3

ANEXX	22
4.1 Publications from the Kidney Transplant Unit of the Nephrology Department at Vall d'Hebron University Hospital	23
4.2 Research projects of the Nephrology Department at Vall d'Hebron University Hospital	30

1

**Vall d'Hebron
University Hospital**




The Vall d'Hebron University Hospital is a health, teaching and research complex, at the service of health and patients. It is the largest complex in Catalonia and one of the largest in the Spanish State. It is geographically located at the foot of the Collserola mountain range, north of the city of Barcelona and its area of influence.

Structured in three large healthcare centers: General Hospital, Children's Hospital and Women's Hospital and Traumatology, Rehabilitation and Burns Hospital, the complex also has the Pere Virgili Health Park, located in a nearby area, where the Surgery Unit is located without Income, and extends its activity to different Primary Care Centers (CAP) in the territory.

With more than 1,000 beds, the Hospital is committed to a management model that places the patient at the center of its actions and acquires a commitment to the future through teaching and innovation, while promoting participation in Catalan, state and international projects of research. Quality is, therefore, a benchmark for the Hospital's professionals, which is why it has acquired recognized national and international prestige and participates in the initiatives of the Department of Health and the public company Institut Català de la Salut, to which it belongs.

1.1 THE HOSPITAL IN FIGURES



1.2 REFERENCE CENTER IN TERCARISM AND HIGH COMPLEXITY

We are a reference center of the National Health System (Spanish territory) for highly complex procedures in both adults and children and tertiary references for most of the highly complex medical and surgical processes and procedures in both Catalonia and Spain or at international level. This is possible thanks to the knowledge of our professionals that covers all health-related disciplines, and in the use of pioneering technologies.



1.2.1 Certifications and accreditations

We are the State hospital with the most European reference networks (known as ERN, for its acronym in English). We participate as a highly specialized health center in 10 minority disease networks, which allows us to share resources and knowledge with other top-level European hospitals

CSUR - Centers, Services and Reference Units of the National Health System

Adult and child

- Hereditary angioedema
- Hereditary ataxias and paraplegias
- Familial heart disease
- Congenital coagulopathy
- Exstrophy-epispadias complex (bladder exstrophy, epispadias and cloacal exstrophy)
- Multiple sclerosis
- Systemic autoimmune diseases
- Complex glomerular diseases
- Congenital metabolic diseases
- Rare neuromuscular diseases
- Rare diseases with movement disorders
- Imported tropical diseases
- Hereditary erythropathology
- Primary immunodeficiencies
- Mastocytosis
- Complex hypothalamic-pituitary pathology
- Critical burns
- Complex ocular surface reconstruction. Keratoprosthesis
- Reconstruction of the auricle
- Congenital bone marrow failure syndromes
- Pediatric and adult lung transplantation

Adult

- Congenital heart disease
- Autoinflammatory diseases
- Pelvic osteotomy in hip dysplasia
- Sarcomas and other musculoskeletal tumors
- Treatment of resistant osteoarticular infections
- Orbital tumors in adults

Children

- Complex heart disease in pediatric patients
- Severe pediatric kidney disease and dialysis treatment
- Complex pediatric pulmonary hypertension
- Neuroblastoma
- Complex pediatric neurosurgery
- Pediatric orthopedics
- Sarcomas in childhood
- Pediatric heart transplantation
- Pediatric liver transplantation
- Pediatric allogeneic hematopoietic stem cell transplantation
- Pediatric kidney transplantation

ERN - EUROPEAN REFERENCE NETWORKS

Adult and child

- Craniofacial anomalies and ear, nose and throat disorders (CRANIO)
- Rare Adult Cancers - Solid Tumors (EURACAN)
- Heart Diseases (GUARD-HEART)
- Hematologic Diseases (EuroBloodNet)
- Liver Diseases (RARE-LIVER)
- Neuromuscular Diseases (EURO-NMD)
- Rare Bone Diseases (BOND)
- Rare Urogenital Diseases and Complex Conditions (eUROGEN)
- Rare Multisystem Vascular Diseases (VASCERN)
- Rare Congenital Malformations and Intellectual Disabilities (ITHACA)
- Endocrine Pathology (ENDO-ERN)
- Renal Pathology (ERKNet)
- Respiratory Pathology (ERN LUNG)
- Neurological Pathologies (ERN RND)
- Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET)

Pediatric

- Cancer Pediatric - oncohematology (PaedCan)
- Hereditary metabolic disorders (MetabERN)
- Immunodeficiencies, autoinflammatory and autoimmune diseases (RITA)
- Hereditary and congenital diseases (ERNICA)
- Urogenital diseases and conditions (eUROGEN)
- Pediatric transplantation (TRANSPLANT-CHILD)

UNE-EN-1450 9001:2015

- Clinical Laboratories
- Hospital pharmacy
- Physics and Radiological Protection
- Radiation Oncology
- Diagnostic Imaging Institute

XUECS CATSALUT UNIDADES DE EXPERTEZ CLÍNICA EN ENFERMEDADES MINORITARIAS

Adult and child

- Epileptic diseases
- Immune diseases: area of primary immunodeficiencies
- Immune diseases: area of autoinflammatory diseases
- Immune diseases: area of systemic autoimmune diseases
- Hereditary metabolic diseases
- Rare endocrine diseases
- Rare non-oncological hematological diseases
- Rare neuromuscular diseases
- Rare renal diseases
- Respiratory diseases
- Hemophilia and congenital coagulopathies
- Genetically based cognitive behavioral diseases in paediatrics

BPSO BEST PRACTICE SOPTLIGHT ORGANIZATION

- Implementation and Evaluation of Good Practice Guides of the Registered Nurses Association d'Ontario



1.3 TEACHING

We understand teaching as a strategic axis of the health system, which must be aimed at improving care and its quality. We contribute to training professionals committed to society, welcoming to patients, governed by ethical and deontological principles, active in research, innovators and experts. Our commitment to specialized health training is supported by a long and consolidated teaching career, which began in 1968, when we were among the first to launch the MIR system. We are currently one of the largest training hospitals in the State, with **167 accredited places in 50 specialties**, which can be accessed by graduates in medicine, pharmacy, psychology, biology, chemistry, physics, and graduates and graduates in nursing.

Currently, the training of specialists is carried out in the following hospital specialties:

Allergology

Anesthesiology and resuscitation

Angiology and vascular surgery

Cardiology

Cardiovascular surgery

Clinical biochemistry

Clinical neurophysiology

Clinical pharmacology

Clinical psychology

Dermatology MQ and venereology

Digestive system

Endocrinology and nutrition

General and digestive system surgery

Geriatrics

Hematology and haemotherapy

Hospital pharmacy

Hospital radiophysics

Immunology

Intensive care medicine

Internal medicine

Medical oncology

Mental health nursing

Microbiology and parasitology

Nephrology

Neurology

Neurosurgery

Nuclear medicine

Obstetric-gynecological nursing

Obstetrics and gynecology

Occupational medicine

Occupational nursing

Ophthalmology

Oral and maxillofacial surgery

Orthopedic surgery and traumatology

Otorhinolaryngology

Pathological anatomy

Pediatric nursing

Pediatric surgery

Pediatrics and specific areas

Physical medicine and rehabilitation

Plastic, aesthetic and reconstructive surgery

Preventive medicine and public health

Psychiatry

Pulmonology

Radiation oncology

Radiodiagnosis

Radiopharmacy

Rheumatology

Thoracic surgery

Urology



El Hospital Universitari Vall d'Hebron es y quiere ser un **hospital formador**.

1.4 RESEARCH

The Vall d'Hebron University Hospital, through the Vall d'Hebron Institute of Research (VHIR) promotes and develops biosanitary research and innovation , aimed at finding solutions to the health problems of citizens and with the desire to contribute to the scientific, educational, social and economic development of its area of competence.

The Research Institute currently leads:

71 Research groups	15,288 Impact factor
2.179 Professionals	975 Active clinical trials
1.629 Scientific publications per year	35 Families of licensed patents

2

**Advanced
Training course**




2.1 PRESENTATION

At our center, the different solid organ transplant programmes are organized within a cross-sectional healthcare area of common expertise as a Transplant center, ensuring that all adult patients receiving a solid organ transplant—whether renal, hepatic, or pulmonary—are admitted to a common hospitalization area. This structure facilitates interaction among all professionals dedicated to transplantation, both in the surgical (Thoracic, Liver, and Urological surgeons) and in the medical field (Infectious disease specialists, Microbiologists, Hepatologists, Pulmonologists, and Nephrologists).

Number of different solid organ transplants over time				
	2023		2024	
	Pediatric	Adults	Pediatric	Adults
Heart	12	-	8	-
Liver	25	65	8	72
Lung	3	99	8	103
Kidney	14	181	16	168
Total	54	345	40	343

Source: Catalan Transplant Organization (OCATT)

The **Kidney Transplant Unit (KTU)** of Vall d'Hebron University Hospital initiated its kidney transplant program back in 1975 and has since performed over 1,600 kidney transplants. In recent years, the program has expanded from 90-100 transplants per year to approximately 170-180 annual procedures.



The KTU at our center offers all possible transplant programs, including:

- Standard-criteria and expanded-criteria deceased donor kidney transplants.
- Kidney transplants from death-cardiac donors, both controlled and uncontrolled.
- Living donor kidney transplants.

Additionally, the following special programs are conducted:

- Desensitization of HLA-incompatible recipients, with relevant participation in clinical trials using new immunosuppressive molecules and strategies.
- Desensitization of ABO-incompatible recipients from living donors.
- Paired kidney exchange transplantation
- Dual pediatric donor kidney transplantation with *en bloc* implantation into an adult recipient.
- Transplantation from hepatitis C virus (HCV) positive donors to HCV-positive recipients, and transplantation of HIV-positive recipients.

The **KTU** directly participates and leads multiple projects and clinical trials promoted both by the pharmaceutical industry and by transplant researchers in the context of national and international competitive grants. Most patients transplanted in our unit participate in research studies.

Our **Unit** has extensive experience in research, mainly endorsed by four key lines of investigation, focusing on translational research from both a clinical and experimental perspective done at our **Nephrology and Kidney Transplantation Laboratory – Research Institute (web)**.

The main research areas include:

- Evaluation and development of new diagnostic strategies and/or non-invasive biomarkers for graft rejection in renal and other solid organ transplants.
- Study of the risk of opportunistic infections in transplantation using new diagnostic tools, mainly against **Cytomegalovirus (CMV), SARS-CoV-2, BK and EBV virus**.
- Study and development of new therapeutic molecules to inhibit the **allogeneic response** to prevent graft rejection in experimental transplantation models.
- Epidemiological clinical studies with large datasets aimed at analyzing transplant clinical outcomes in various specific areas.

- Study of **histopathological lesions** in kidney grafts based on advanced diagnostic technologies and their association with immunological biomarkers.

The **KTU** has 7 senior transplant nephrologists devoted to distinct areas in the kidney transplant field and among, them, there are **five senior researchers**, who are principal investigators in competitive grants. Also, the department has **two postdoctoral basic researchers, 2 predoctoral students, 1 computational biologist and 3 specialized laboratory technicians**.

The group has its own **research laboratory** and is currently leading three **internationally competitive projects** funded by the European Community (**Horizon 2020, Horizon Europe 2021-2027, and an Era-Permed**) and furthermore, leads **5 projects funded by the Carlos III Health Institute (ISCIII), one project funded by the LaCaixa foundation and another one by the Catalan Institute of Health (PERIS)**.

The **KTU research team** has a strong track record of **scientific publications** in both national and, high-impact factor **international journals**.

(The annex to this document includes a list of the latest publications led by the **team**, as well as the details of projects funded by different public entities and scientific societies over the past four years.)

2.2 JUSTIFICATION

Kidney transplantation is the best treatment for patients with **End-stage renal disease (ESRD)**, as it offers the highest survival rates with improved quality of life at a lower cost.

Organs for transplantation are a **scarce resource**, and the first step toward improving patient access to transplantation requires a **healthcare system with an efficient organization** for detecting and obtaining organs from potential donors.

In this regard, **Spain has a model organizational system** that utilizes all possible sources of organ donation (cadaveric, living, donation after circulatory death, and crossed kidney transplantation). As a result, **51% of patients with ESRD currently have a functional kidney graft**.

Spain is an **active player in both basic and clinical research** in the field of transplantation, with numerous **collaborative projects** between different centers. This is largely due to the participation of hospitals in the **Renal Research Network (RICORS) of the Carlos III Health Institute**.

The **Advanced Training in Kidney Transplantation** program aims to **expand the theoretical and practical training of nephrology specialists** in the clinical, organizational, and research aspects of kidney transplantation.

2.3 COURSE PROGRAM

2.3.1 Course Syllabus

- Criteria for **kidney transplant waitlist inclusion**.
- Criteria for **accepting cadaveric donor organs for kidney transplantation**.
- Criteria for **recipient selection for cadaveric donor kidney transplantation**.
- Criteria for **living donor kidney selection**.
- National **Kidney Transplant Echange Program**.
- National and regional programs for **transplantation of highly sensitized patients**.
- **Transplant immunology**: Interpretation of new techniques for detecting anti-HLA antibodies and cellular sensitization.



- **Immunosuppressive treatments and strategies** based on immunological risk and donor characteristics.
 - **Desensitization therapies** for recipients with a positive crossmatch.
 - **Management** postoperative **medical-surgical complications**.
 - **Biopsy indications** and graft histopathological diagnosis.
 - Treatment of **acute cellular and humoral rejection**.
 - Use of **new immunological tools** to assess the risk of **CMV and BK virus** infections.
 - Management of **post-transplant infections**.
 - Diagnosis and management of **chronic graft dysfunction**.
 - Post-transplant **cardiovascular complications**.
 - **Cancer and transplantation**.
 - Special transplant programs:
 - HIV-positive recipient transplantation.
 - Transplantation from HCV-positive donors to HCV-positive recipients.
 - Pediatric en bloc kidney transplantation into adult recipients.
 - **Communication techniques** for conferences and congresses.
 - **Database management and statistical fundamentals**.
 - **Clinical trial design and organization**.
 - Diagnostic and therapeutic techniques in **experimental transplant models**.
 - Participation in a **supervised research project** in the field of kidney transplantation.

2.3.2 Course objectives

Main Objectives

- Acquire solid training in the **clinical management of different kidney transplant modalities**.
 - Gain knowledge to **design and conduct clinical research projects** in kidney transplantation.
 - Acquire experience in **translational and experimental clinical research** in transplantation.

Specific Objectives

- Understand the **Spanish transplant model** and its applicability to other settings.
- Develop skills in **anatomopathological diagnosis of kidney biopsies** and their clinicopathological correlations.
- Evaluate **immunological risk** for both rejection and opportunistic infections using **standard and novel biomarkers**.

2.3.3 Competencies to be Acquired

Specific Competencies

- Selection of **donors and recipients** for the transplant waitlist.
- Evaluation of **alloimmune risk stratification**.
- Selection of **immunosuppressive treatments**.

- Management of **highly sensitized patients** for access to transplantation and to prevent humoral rejection.
- Postoperative **immediate care, early complication diagnosis, and treatment.**
- Long-term **outpatient follow-up** of transplant recipients.
- Assessment of **renal biopsy findings.**
- Interpretation of **renal allograft ultrasound.**
- Cardiovascular risk evaluation (**carotid ultrasound, pulse wave velocity, ankle-brachial index, endothelial dysfunction**).
- **24-hour blood pressure monitoring.**
- Development of **Phase II, III, and IV clinical trials.**
- Design of **databases and statistical analyses.**
- Development of a **clinical, translational, or basic research project.**

Transversal Competencies

- Apply bioethical principles in clinical practice.
- Perform critical analysis and review of research topics.
- Work effectively in multidisciplinary teams.
- Integrate clinical practice with teaching and research.

2.3.4 Teaching Methodology

The learning methodology is based on daily attendance at the Kidney Transplant Unit's clinical activities and participation in training activities that coincide with the training period.

Active participation in the sessions scheduled in the service is expected:

- Daily shift change session from the previous day.
- Scientific session (Thursdays, 8:15 to 9:30 a.m.).
- Participation in the Transplant Committee (Wednesdays, 8:00 to 8:30 a.m.). This session is attended by nephrologists, urologists, and anesthesiologists, and cases are reviewed for inclusion on the waiting list.
- Weekly pathology sessions (Thursdays, 3:00 to 4:30 p.m.).
- Transplant Unit clinical research session (Mondays, 3:30 to 4:15 p.m.).
- Research laboratory session (Wednesdays, 3:00 PM to 4:00 PM).
- Multidisciplinary session on solid organ transplantation (last Wednesday of the month, 3:00 PM to 4:00 PM).
- Discussion and proposal of a supervised research project to be carried out during the training stay.

2.3.5 Evaluation

Continuous Assessment

- Continuous assessment of knowledge and attitudes in clinical practice.
- Written tests for any training activities carried out during the training that require them.



Final Assessment

- Presentation and evaluation of the research project.

2.4 MANAGEMENT AND TEACHING STAFF

Program Director:

Oriol Bestard

Head of Service

oriol.bestard@vallhebron.cat

Nephrology Department

Secretary

Ms. Rosa Pérez

Tel. 00 34 93 274 64 76

Francesc Josep Moreso

Head of Transplant Clinic

francescJosep.moreso@vallhebron.cat

Teaching collaborators of the Kidney Transplant Unit:

Specialist Physicians of the Service

Dr. Joana Sellares

Dr. María Meneghini

Dr. Irina Torres

Dr. Delphine Kervella

Dr. Zaira Castañeda

Dr. Manel Perelló

Postdoctoral Researchers

Dr. Elena Crespo

Dr. Laura Donadeu

Dr. Franc Casanova

Predoctoral Researchers

Anna Martínez Lacalle

Claudia Carrera

Advanced Practice Kidney Transplant Nurse

Ms. Irene Sánchez

Clinical Trials Unit and Laboratory Technicians

Emma Pardo

Cristina Font

Mariona Juvé

Renal Pathology Department

Dr. Alejandra Gabaldón

Immunology Department

Dr. Mónica Martínez-Gallo

Transplant Coordination

Dr. Alberto Sandiumenge

Radiology

Dr. Richard Mast

Urology Department

Dr. Enric Trilla

Dr. Carles Raventós

Dr. Enric Miret

Pediatric Nephrology





Dra. Gema Ariceta

3

Procedures and Conditions



3.1 GENERAL COURSE DATA

	Program name	Advanced Training Course in Kidney Transplantation
	Program type	Advanced Training
	Modality	In-person
	Teaching Center	Hospital Universitari Vall d'Hebron
	Languages	Spanish, Catalan or English
	Places available	1
	Who is it addressed to?	Training for specialists with officially recognized degrees in Nephrology with objective knowledge and skills specific to the specialty
	Duration	12 months (October 1, 2025 – September 30, 2026)
	End of registration period	May 30, 2025
	Schedule	Coinciding with service working hours
	Dedication	Full time (non-exclusive)
	Prize	2.900 euros

3.2 REGISTRATION PROCEDURES

Documentation to be provided to take part in the selection process:

- [Registration form for Advanced Training.](#)
- Photocopy of DNI/NIE/Passport.
- Photocopy of the visa in case the country of origin requires it.
- Concise and updated Curriculum Vitae (maximum three pages).
- Copy of the Medicine degree.
- Copy of the specialist title.
- Written explaining the reasons for your interest in the program you are opting for. Please include the documentation you consider of interest.

Documentation to provide once the place is confirmed:

- Certificate of negative sexual offences in force.
- Professional membership card (only for Spanish professionals).
- [Vaccination medical report from the U. Vall d'Hebron Hospital](#) (only for foreign professionals).

- Photocopy of the visa in case the country of origin requires it (only for foreign professionals).
- Photocopy of the accident and health care insurance (only for foreign professionals).
- Photocopy of the civil liability insurance (only for foreign professionals).
- If applicable, letters of recommendation from relevant people from your workplace or others, as well as from the Director of the Training Programme at the centre where you were trained.

Photocopies of both insurance policies must clearly identify the name of the insurance company and the policy number. These documents are essential so that the training period can begin. All documentation to be provided to apply for admission to the program must be sent by email to: aulavh@vallhebron.cat.

Apart from this documentation, if the course management deems it necessary, the interested party may be asked for a personal interview.

The documentation to be provided once the place has been confirmed must be sent at least one month before the start date, otherwise the registration will be cancelled.

3.3 PROGRAM APPROVAL

Once the candidate selection process is completed, the Aula Vall d'Hebron will send the resolution of acceptance to the Advanced Training by email to the chosen candidate.

Once the place is confirmed by the interested party, the registration amount to be determined based on the dates and duration of the program will be processed by bank transfer.

3.4 REQUIREMENTS FOR STAYING AT THE CENTER

3.4.1 Relationship of professionals with the Vall d'Hebron University Hospital

The professional admitted to the program will access the Hospital premises for the exclusive purpose of training and recycling. The admitted professional has an "observer" role, so they will not be responsible for the care of inpatients, outpatients or emergency patients, nor sign clinical documentation.

Acceptance into the course will not imply any type of employment relationship with the Hospital. No type of financial compensation or remuneration will be received from the Hospital during the duration of your training.

In addition, the professional must have an accident policy and insurance that covers medical care. The Hospital is exempt from any type of claim, regarding common illness or accident that could occur as a result of your stay in the center's facilities, because your connection with the center is exclusively for training.

You will be subject to the internal rules and regulations of the Hospital, as well as the specific rules of the service or unit where you carry out the training.

You must demonstrate a commitment to the mission, vision and values of the center common to the service and be willing to integrate with the team.

He will show a clear interest and respect for the specialty and the center.

3.4.2 Activities

The professional will have the training schedule established with the training director based on the program. You will be obliged to know and respect Spanish legislation regarding the protection of personal data (Law 15/1999 of December 13) and guarantee professional secrecy both during your stay at the Hospital and afterwards.



You must have a civil liability policy that covers the risks that you may incur as a result of the activities carried out during your training period.

3.5 ADMISSION PROCESS AT THE CENTER

On the day of incorporation, the interested party must go to the Teaching Directorate to complete the admission process to the center.

Aula Vall d'Hebron

Dirección de Docencia
Pl. 5ª Hospital de Traumatología
Paseo Vall d'Hebron 119-129
08035 Barcelona (Spain)

Likewise, the interested party must sign a permanence commitment specifying that they know, understand and accept the conditions established by the Hospital, and a data confidentiality commitment.

3.6 CANCELLATION OF THE TRAINING PROGRAM

In the case of non-compliance with the established requirements, the Hospital reserves the right to revoke the training permit at any time without the right to claim.

On the other hand, in the event that the interested party submits the cancellation of the training program before its start, and always for reasons of force majeure, part of the registration fee that has been contributed to confirm the place will be refunded. Likewise, the program management may propose to the interested party the possibility of postponing the start of training to the following year.

3.7 CERTIFICATION

At the end of the training period, the Teaching Directorate will issue a certificate of attendance in view of the report provided by the program directors.

4

Anexx



PUBLICATIONS FROM THE KIDNEY TRANSPLANT UNIT OF THE NEPHROLOGY SERVICE OF VALL D'HEBRON UNIVERSITY HOSPITAL IN THE LAST 5 YEARS

List of the most relevant publications produced by the unit in the last 5 years:

- 1.** Sablik M, Sannier A, Raynaud M, Goutaudier V, Divard G, Astor BC, Weng P, Smith J, Garro R, Warady BA, Zahr RS, Twombly K, Dharnidharka VR, Dandamudi RS, Fila M, Huang E, Sellier-Leclerc AL, Tönshoff B, Rabant M, Verine J, Del Bello A, Berney T, Boyer O, Catar RA, Danger R, Giral M, Yoo D, Girardin FR, Alsadi A, Gourraud PA, Morelon E, Le Quintrec M, Try M, Villard J, Zhong W, Bestard O, Budde K, Chauveau B, Couzi L, Brouard S, Hogan J, Legendre C, Anglicheau D, Aubert O, Kamar N, Lefaucheur C, Loupy A.
Microvascular Inflammation of Kidney Allografts and Clinical Outcomes.
N Engl J Med. 2024 Oct 24.
doi: 10.1056/NEJMoa2408835.
- 2.** Chamoun, B.; Torres, I.B.; Gabaldón, A.; Juvé, T.; Meneghini, M.; Zúñiga, J.M.; Sellarés, J.; Perelló, M.; Serón, D.; Bestard, O.; Moreso, F.
Expression of Rejection-Associated Transcripts in Early Protocol Renal Transplant Biopsies Is Associated with Tacrolimus Exposure and Graft Outcome
International Journal of Molecular Sciences 2024; 25 (6): 3189
doi: 10.3390/ijms25063189
PMID: 38542163
Impact factor 2023: 4,900 (Q1 – 66/313 Biochemistry & Molecular Biology)
- 3.** Donadeu L, Gomez-Olles S, Casanova F, Torija A, Lopez-Meseguer M, Boada-Pérez M, Kervella D, Crespo E, Carrera-Muñoz C, Campos-Varela I, Castells L, Cortese MF, Esperalba J, Fernández-Naval C, Quintero J, Muñoz M, Agüero F, Gonzalez-Costello J, Lladó L, Favà A, Cañas L, Del Mar de la Hoz-Caballero M, Meneghini M, Torres IB, Juvé M, Hafkamp F, Vila M, Robles AG, Buzón MJ, Toapanta N, Zúñiga JM, Monforte V, Saez-Giménez B, Len O, Arcos IL, Miret E, Ariceta G, Pardo E, Martínez X, Moreso F, Bestard O.
Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation.
Front Immunol. 2024 Oct 8;15:1463769.
doi: 10.3389/fimmu.2024.1463769.
- 4.** Goutaudier V, Danger R, Catar RA, Racapé M, Philippe A, Elias M, Raynaud M, Aubert O, Bouton D, Girardin F, Vicaut É, Yaiche S, Demotes J, Heidecke H, Taupin JL, Randoux-Lebrun C, Zaidan M, Papuchon E, Le Mai H, Nguyen TV, Moreso F, Berney T, Villard J, Legendre C, Dragun D, Papalois V, Potena L, Giral M, Gourraud PA, Brouard S, Crespo E, Halleck F, Budde K, Bestard O, Loupy A, Lefaucheur C; EU-TRAIN Consortium.
Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN).
Kidney Int. 2024 Nov;106(5):943-960.
doi: 10.1016/j.kint.2024.07.027. Epub 2024 Aug 27.
PMID: 39197587
- 5.** Torija A, Matignon M, Vincenti F, Casanova-Ferrer F, Pilon C, Tambur AR, Donadeu L, Crespo E, Kervella D, Meneghini M, Torres IB, Hafkamp F, Martinez-Lacalle A, Carrera C, Zúñiga J, Brar A, Cruzado J, Gaber AO, Lee H, Montgomery RA, Stegall M, Carmagnat M, Usureau C, Moreso F, Grimbert P, Bestard O.
Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates.
Am J Transplant. 2025 Jan;25(1):88-101.
doi: 10.1016/j.ajt.2024.08.004.

- 6.** Bestard O, Augustine J, Wee A, Poggio E, Mannon RB, Ansari MJ, Bhati C, Maluf D, Benken S, Leca N, La Manna G, Samaniego-Picota M, Shawar S, Concepcion BP, Rostaing L, Alberici F, O'Connell P, Chang A, Salem F, Kattan MW, Gallon L, Donovan MJ.
Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection.
Am J Transplant. 2024 Mar;24 (3):436-447.
doi: 10.1016/j.ajt.2023.09.021.
- 7.** Donadeu, L.; Jouve, T.; Bin, S.; Hartzell, S.; Crespo, E.; Torija, A.; Jarque, M.; Kervella, D.; Zúñiga, J.; Zhang, W.; Sun, Z.; Verlató, A.; Martínez-Gallo, M.; Font-Miñarro, C.; Meneghini, M.; Toapanta, N.; Torres, I.B.; Sellarés, J.; Perelló, M.; Kaminski, H.; Couzi, L.; Loupy, A.; La Manna, G.; Moreso, F.; Cravedi, P.; Bestard, O.
High-dimensional Mass Cytometry identified circulating Natural Killer T-cell subsets associated with protection from Cytomegalovirus infection in kidney transplant recipients
Kidney International 2024; 27:S0085-2538(24)00310-7
doi: 10.1016/j.kint.2024.03.027
PMID: 38685562
Impact factor 2023: 14,800 (Q1 – 4/126 Urology & Nephrology)
- 8.** Toapanta, N.; Comas, J.; Revuelta, I.; Manonelles, A.; Facundo, C.; Pérez-Saez, M.J.; Vila, A.; Arcos, E.; Tort, J.; Giral, M.; Naesens, M.; Kuypers, D.; Asberg, A.; Moreso, F.; Bestard, O.; EKITE consortium
Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort
Transplant International 2024; 37: 13452
doi: 10.3389/ti.2024.13452
PMID: 39263600
Impact factor 2023: 2,700 (Q2 – 12/31 Transplantation)
- 9.** Bestard, O.; Kaminski, H.; Couzi, L.; Fernández-Ruiz, M.; Manuel, O.
Cytomegalovirus cell-mediated immunity. Ready for routine use?
Transplant International 2023; 36: 11963
doi: 10.3389/ti.2023.11963
PMID: 38020746
Impact factor: 2,700 (Q2 – 12/31 Transplantation)
- 10.** Kervella, D.; Torija, A.; Zúñiga, J.M.; Bestard, O.
How to measure human leukocyte antigen-specific B cells
Current Opinion in Organ Transplantation 2023; 28 (5): 345-354
doi: 10.1097/MOT.0000000000001097
PMID: 37678170
Impact factor: 1,800 (Q3 – 19/31 Transplantation)
- 11.** Meneghini, M.; Perona, A.; Crespo, E.; Bemelman, F.; Reinke, P.; Viklicky, O.; Giral, M.; Palou, E.; Torija, A.; Donadeu, L.; Melilli, E.; Zúñiga, J.; Sefrin, A.; Lachmann, N.; Hu, L.; Hrubá, P.; Guillot-Gueguen, C.; Brouard, S.; Grinyó, J.M.; Bestard, O.
On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes
Frontiers in Immunology 2022; ;13: 924825
doi: 10.3389/fimmu.2022.924825
PMID: 36248818
Impact factor: 7,300 (Q1 - 35/161 Immunology)



- 12.** Pernin V, Meneghini M, Torija A, Jouve T, Del Bello A, Sanz-Muñoz I, Eiros JM, Donadeu L, Polo C, Morandeira F, Navarro S, Masuet C, Favà A, LeQuintrec M, Kamar N, Crespo E, Bestard O. Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept. *Front Immunol.* 2022 Jul 29;13: 918887. doi: 10.3389/fimmu.2022.918887. eCollection 2022. PMID: 35967428
Impact factor 2021: 8.786 (Q1 / Immunology)
- 13.** Guiteras J, Crespo E, Fontova P, Bolaños N, Gomà M, Castaño E, Bestard O, Grinyó JM, Torras J. Dual Costimulatory and Coinhibitory Targeting with a Hybrid Fusion Protein as an Immunomodulatory Therapy in Lupus Nephritis Mice Models. *Int J Mol Sci.* 2022 Jul 29;23 (15):8411. doi: 10.3390/ijms23158411. Impact factor 2020: 5,924 (Q1 / Biochemistry & Molecular Biology)
- 14.** Crespo E, Vidal-Alabró A, Jouve T, Fontova P, Stein M, Mocka S, Meneghini M, Sefrin A, Hrubá P, Gomà M, Torija A, Donadeu L, Favà A, Cruzado JM, Melilli E, Moreso F, Viklicky O, Bemelman F, Reinke P, Grinyó J, Lloberas N, Bestard O. Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation. *Front Immunol.* 2022 Jun 27;13:869554. doi: 10.3389/fimmu.2022.869554. eCollection 2022. Impact factor 2021: 8.786 (Q1 / Immunology)
- 15.** Donadeu L, Tiraboschi JM, Scévola S, Torija A, Meneghini M, Jouve T, Favà A, Calatayud L, Ardanuy C, Cidraque I, Preyer R, Strecker K, Lozano JJ, Podzamczek D, Crespo E, Bestard O. Long-lasting adaptive immune memory specific to SARS-CoV-2 in convalescent coronavirus disease 2019 stable people with HIV. *AIDS.* 2022 Aug 1;36(10):1373-1382. doi: 10.1097/QAD.0000000000003276. Epub 2022 Jun 22. PMID: 35730384
Impact factor 2021: 4.632
- 16.** Bestard O, Thauinat O, Bellini MI, Böhmig GA, Budde K, Claas F, Couzi L, Furian L, Heemann U, Mamode N, Oberbauer R, Pengel L, Schneeberger S, Naesens M. Alloimmune Risk Stratification for Kidney Transplant Rejection. *Transpl Int.* 2022 May 20;35:10138. doi: 10.3389/ti.2022.10138. eCollection 2022. ISSN: 1473-5571
Impact factor: 3,782
- 17.** Bestard, O.; Crespo, E. Disarming the old foe. Restoring T-cell immune function with mTor-inhibitors to tackle cytomegalovirus infection *Journal of the American Society of Nephrology* 2022; 33 (1): 6-8
doi: 10.1681/ASN.2021111471 PMID: 34969818

ISSN: 1046-6673

Impact factor 2020: 10,121 (Q1 / Urology & Nephrology)

- 18.** Bestard, O.; Jouve, T.; Castells, L.; Lopez, M.; Muñoz, M.; Crespo, E.; Toapanta, N.; Esperalba, J.; Campos-Varela, I.; Pont, T.; Len, O.; Campins, M.; Moreso, F.
Reconciling short-term clinical and immunological outcomes of SARS-CoV-2 vaccination in solid organ transplant recipients
American Journal of Transplantation 2022; 22 (2): 673-675
doi: 10.1111/ajt.16855 PMID: 34554648
ISSN: 1600-613
Impact factor 2020: 8,086 (Q1 / Transplantation)
- 19.** Crespo, E.; Vidal-Alabro, A.; Jouve, T.; Fontova, P.; Stein, M.; Mocka, S.; Meneghini, M.; Sefrin, A.; Hrubá, P.; Gomà, M.; Torija, A.; Favà, A.; Cruzado, J.M.; Melilli, E.; Moreso, F.; Viklicky, O.; Bemelman, F.; Reinke, P.; Grinyó, J.M.; Lloberas, N.; Bestard, O.
Tacrolimus single nucleotide polymorphisms (SNPs) and preformed T and B cell alloimmune memory improve current pretransplant rejection-risk stratification in kidney Transplantation
Frontiers in Immunology 2002; [in press]
ISSN: 1664-3224
Impact factor 2020: 7,561 (Q1 / Immunology)
- 20.** Favà, A.; Donadeu, L.; Jouve, T.; Gonzalez-Costello, J.; Lladó, L.; Santana, C.; Toapanta, N.; Lopez, M.; Pernin, V.; Facundo, C.; Cabañas, N.S.; Thauat, O.; Crespo, M.; Llinàs, L.; Revuelta, I.; Sabé, N.; Rombauts, A.; Calatayud, L.; Ardanuy, C.; Esperalba, J.; Fernandez, C.; Lozano, J.J.; Preyer, R.; Strecker, K.; Couceiro, C.; García-Romero, E.; Cachero, A.; Meneghini, M.; Torija, A.; Le Quintrec, M.; Melilli, E.; Cruzado, J.M.; Polo, C.; Moreso, F.; Crespo, E.; Bestard, O.
A comprehensive assessment of long-term SARS-CoV-2-specific immune memory in convalescent COVID-19 solid organ transplant recipients
Kidney International 2022; S0085-2538(22)00029-1
doi: 10.1016/j.kint.2021.12.029 PMID: 35124011
ISSN: 0085-2538
Impact factor 2020: 10,612 (Q1 / Urology & Nephrology)
- 21.** Bestard, O.; Couzi, L.; Crespo, M.; Kessar, N.; Thauat, O.
Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group
Transplant International 2021; 34 (6): 1005-1018
doi: 10.1111/tri.13874 PMID: 33786891
ISSN: 0934-0874
Impact factor: 3,782 (Q2 / Transplantation – Q1 / Surgery)
- 22.** Bestard, O.; Meneghini, M.; Crespo, E.; Bemelman, F.; Koch, M.; Volk, H.D.; Viklicky, O.; Giral, M.; Banas, B.; Ruiz, J.C.; Melilli, E.; Hu, L.; van Duivenvoorden, R.; Nashan, B.; Thaiss, F.; Otto, N.M.; Bold, G.; Stein, M.; Sefrin, A.; Lachmann, N.; Hrubá, P.; Stranavova, L.; Brouard, S.; Braudeau, C.; Blancho, G.; Banas, M.; Irure, J.; Christakoudi, S.; Sanchez-Fueyo, A.; Wood, K.J.; Reinke, P.; Grinyó, J.M.



Preformed T-cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with Tacrolimus monotherapy in Kidney Transplantation. Results of the CELLIMIN trial

American Journal of Transplantation 2021; 21 (8): 2833-2845

doi: 10.1111/ajt.16563 PMID: 33725408

ISSN: 1600-6135

Impact factor 2020: 8,086 (Q1 / Transplantation)

- 23.** Donadeu, L.; Revilla-López, E.; Jarque, M.; Crespo, E.; Torija, A.; Bravo, C.; Los Arcos, I.; Meneghini, M.; Favà, A.; Román, A.; Monforte, V.; Bestard, O.

CMV-specific cell-mediated immunity predicts a high level of CMV replication after prophylaxis withdrawal in lung transplant recipients

Journal of Infectious Diseases 2021; 224 (8): 526-531

doi: 10.1093/infdis/jiaa727 PMID: 33245359

ISSN: 0022-1899

Impact factor 2020: 5,226 (Q1 / Infectious Diseases)

- 24.** Favà, A.; Donadeu, L.; Sabé, N.; Pernin, V.; González-Costello, J.; Lladó, L.; Meneghini, M.; García-Romero, E.; Cachero, A.; Torija, A.; Rodríguez-Urquía, R.; Crespo, E.; Teubel, I.; Melilli, E.; Montero, N.; Manonelles, A.; Preyer, R.; Strecker, K.; Ovize, A.; Lozano, J.J.; Sidorova, J.; Cruzado, J.M.; Le Quintrec, M.; Thaumat, O.; Bestard, O.

SARS-CoV-2-specific serological and functional T-cell immune responses during acute and early COVID-19 convalescence in solid organ transplantation patients

American Journal of Transplantation 2021; 21 (8): 2749-2761

doi: 10.1111/ajt.16570 PMID: 33756051

ISSN: 1600-6135

Impact factor 2020: 8,086 (Q1 / Transplantation)

- 25.** Guiteras, J.; De Ramon, L.; Crespo, E.; Bolaños, N.; Barcelo-Batllori, S.; Martinez-Valenzuela, L.; Fontova, P.; Jarque, M.; Torija, A.; Bestard, O.; Resina, D.; Grinyó, J.M.; Torras, J.

Dual and opposite costimulatory targeting with a novel human fusion recombinant protein effectively prevents renal warm ischemia reperfusion injury and allograft rejection in murine models

International Journal of Molecular Sciences 2021; 22 (3): 1216

doi: 10.3390/ijms22031216. PMID: 33530581

ISSN: 1422-0067

Impact factor 2020: 5,924 (Q1 / Biochemistry & Molecular Biology)

- 26.** Mastoridis, S.; Londoño, M.C.; Kurt, A.; Kodela, E.; Crespo, E.; Mason, J.; Bestard, O.; Martínez-Llordella, M.; Sánchez-Fueyo, A.

Impact of donor extracellular vesicle release on recipient cell “cross-dressing” following clinical liver and kidney transplantation

American Journal of Transplantation 2021; 21 (7): 2387-2398

doi: 10.1111/ajt.16123 PMID: 32515541

ISSN: 1600-6135

Impact factor 2020: 8,086 (Q1 / Transplantation)

- 27.** Melilli, E.; Cestone, G.; Revuelta, I.; Meneghini, M.; Lladó, L.; Montero, N.; Manonelles, A.; Diaz, M.; Coloma, A.; Torregrosa, V.; Baliellas, C.; Cruzado, J.M.; Diekmann, F.; Grinyó, J.; Bestard, O. Adoption of a novel smart mobile-health application technology to track chronic immunosuppression adherence in solid organ transplantation: results of a prospective, observational, multicentre, pilot study
Clinical Transplantation 2021; 35 (5): e14278
doi: 10.1111/ctr.14278 PMID: 33682207
ISSN: 0902-0063
Impact factor 2020: 2,863 (Q3 / Transplantation – Q2 / Surgery)
- 28.** Meneghini, M.; Crespo, E.; Niemann, M.; Torija, A.; Lloberas, N.; Pernin, V.; Fontova, P.; Melilli, E.; Favà, A.; Montero, N.; Manonelles, A.; Cruzado, J.M.; Palou, E.; Martorell, J.; Grinyó, J.M.; Bestard, O.
Donor/recipient HLA molecular mismatch scores predict primary humoral and cellular alloimmunity in kidney transplantation
Frontiers in Immunology 2021; 11: 623276
doi: 10.3389/fimmu.2020.623276 PMID: 33776988
ISSN: 1664-3224
Impact factor 2020: 7,561 (Q1 / Immunology)
- 29.** Montero, N.; Toapanta, N.; Pallarès, N.; Crespo, M.; Diekmann, F.; Guirado, L.; Esteban, R.; Codina, S.; Melilli, E.; Buxeda, A.; Velis, G.; Torres, I.B.; Revuelta, I.; Moina Andujar, A.; Facundo, C.; Bardají, B.; Riera, I.; Fiol, M.; Cruzado, J.M.; Comas, J.; Giral, M.; Naesens, M.; Asberg, A.; Moreso, F.; Bestard, O.
Deciphering transplant outcomes of expanded kidney allografts donated after controlled circulatory death in the current transplant era. A call for caution
Transplant International 2021; 34 (12): 2494-2506
doi: 10.1111/tri.14131 PMID: 34626501
ISSN: 0934-0874
Impact factor: 3,782 (Q2 / Transplantation – Q1 / Surgery)
- 30.** Del Bello, A.; Thauvat, O.; Le Quintrec, M.; Bestard, O.; Durrbach, A.; Perrin, P.; Gatault, P.; Jambon, F.; Pageaux, G.P.; Lladó, L.; Besch, C.; Barbier, L.; Neau-Cransac, M.; Dumortier, J.; Kamar, N.
Combined liver-kidney transplantation with preformed anti-human leukocyte antigen donor-specific antibodies
Kidney International Reports 2020; 5 (12): 2202-2211
doi: 10.1016/j.ekir.2020.09.018
ISSN: 2468-0249
Impact factor: 4,164 (Q1 / Urology & Nephrology)
- 31.** Favà, A.; Cucchiari, D.; Montero, N.; Toapanta, N.; Centellas, F.J.; Vila-Santandreu, A.; Coloma, A.; Meneghini, M.; Manonelles, A.; Sellarés, J.; Torres, I.; Gelpi, R.; Lorenzo, I.; Ventura-Aguilar, P.; Cofan, F.; Torregrosa, J.V.; Perelló, M.; Facundo, C.; Seron, D.; Oppenheimer, F.; Bestard, O.; Cruzado, J.M.; Moreso, F.; Melilli, E.
Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study
American Journal of Transplantation 2020; 20 (11): 3030-3041



doi: 10.1111/ajt.16246 PMID: 32777153

ISSN: 1600-6135

Impact factor: 8,086 (Q1 / Transplantation)

- 32.** Jarque, M.; Crespo, E.; Melilli, E.; Gutiérrez, A.; Moreso, F.; Guirado, L.; Revuelta, I.; Montero, N.; Torras, J.; Riera, L.; Meneghini, M.; Taco, O.; Manonelles, A.; Paul, J.; Seron, D.; Facundo, C.; Cruzado, J.M.; Gil Vernet, S.; Grinyó, J.M.; Bestard, O.

Cellular immunity to predict the risk of cytomegalovirus infection in kidney transplantation: a prospective, interventional, multicenter clinical trial

Clinical Infectious Diseases 2020; 71 (9): 2375-2385

doi: 10.1093/cid/ciz1209 PMID: 32076718

ISSN: 1058-4838

Impact factor: 9,079 (Q1 / Infectious Diseases)

- 33.** Pineda, S.; Sur, S.; Sigdel, T.; Nguyen, M.; Crespo, E.; Torija, A.; Meneghini, M.; Gomà, M.; Sirota, M.; Bestard, O.; Sarwal, M.M.

Peripheral blood RNA sequencing unravels a differential signature of coding and non-coding genes by types of kidney allograft rejection

Kidney International Reports 2020; 5 (10): 1706-1721

doi: 10.1016/j.ekir.2020.07.023

ISSN: 2468-0249

Impact factor: 4,164 (Q1 / Urology & Nephrology)

- 34.** Torija, A.; Favà, A.; Meneghini, M.; Crespo, E.; Bestard, O.

Novel insights into the pathobiology of humoral alloimmune memory in kidney transplantation

Current Opinion in Organ Transplantation 2020; 25 (1): 15-21

doi: 10.1097/MOT.0000000000000717 PMID: 31815788

ISSN: 1087-2418

Impact factor: 2,640 (Q3 / Transplantation)

- 35.** Waldman, M.; Soler, M.J.; García-Carro, C.; Lightstone, L.; Turner-Stokes, T.; Griffith, M.; Torras, J.; Martínez Valenzuela, L.; Bestard, O.; Geddes, C.; Flossmann, O.; Budge, K.L.; Cantarelli, C.; Fiaccadori, E.; Delsante, M.; Morales, E.; Gutiérrez, E.; Niño-Cruz, J.A.; Martínez-Rueda, A.J.; Comai, G.; Bini, C.; La Manna, G.; Slon, M.F.; Manrique, J.; Agraz, I.; Sinaii, N.; Cravedi, P.

Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring

Kidney International 2020; S0085-2538 (20): 31281-3

doi: 10.1016/j.kint.2020.10.032 PMID: 33181156

ISSN: 0085-2538

Impact factor: 10,612 (Q1 / Urology & Nephrology)

RESEARCH PROJECTS OF THE NEPHROLOGY DEPARTMENT OF THE VALL D'HEBRON UNIVERSITY HOSPITAL

Below are the kidney transplant-related research projects funded by various public entities or scientific societies during the 2017–2025 period.

- **RESET INMUNOLÓGICO PARA PERMITIR EL ACCESO AL TRASPLANTE RENAL HLA COMPATIBLE EN PACIENTES HIPERSENSIBILIZADOS (ESTUDIO RESET)**
Investigador Principal: Oriol Bestard Matamoros
Col-laboradors: Moreso Mateos, Francesc Javier; Torres Rodríguez, Irina Betsabé; Crespo Gimeno, Elena Isabel; Meneghini, Maria Antonia Emilia; Carrera Muñoz, Claudia; Casanova Ferrer, Franc; Kervella, Delphine; Donadeu Casassas, Laura; Sola Soto, Maria; Pérez González, Ana
Entitat finançadora: Ministerio de Ciencia, Innovación y Universidades
Núm. expedient: IC24/00066
- **MANEJO DE LA IMMUNOSUPRESIÓN TRAS EL FRACASO DE UN INJERTO RENAL PARA PREVENIR DE FORMA SEGURA LA SENSIBILIZACIÓN HLA: UN ESTUDIO ABIERTO, PROSPECTIVO MULTICÉNTRICO Y RANDOMIZADO**
Investigadors Principals: Francesc Moreso Mateos i Irina Betsabé Torres Rodríguez
Col-laboradors: Oriol Bestard, Manel Perelló, Irina B. Torres, Joana Sellarés, Maria Meneghini, Edoardo Melilli, Núria Montero, M^a José Pérez-Sáez, Marta Crespo, Dolores Redondo, Carlos Arias, David Cucchiari, Eduard Palou, Carme Facundo, Anna Vila
Entitat finançadora: Instituto de Salud Carlos III - Convocatoria Proyectos Investigación Clínica Independiente
Núm. expedient: IC22/00106
- **DUACEPT, A NOVEL BI-SPECIFIC FUSION PROTEIN TO PREVENT TRANSPLANT REJECTION**
Investigador Principal: Oriol Bestard Matamoros
Col-laboradors: Grinyó Boira, Josep Maria; Crespo Gimeno, Elena Isabel; Bolaños, Núria; Donadeu Casassas, Laura; Kervella, Delphine
Entitat finançadora: Fundació La Caixa - CaixaImpulse Innovation Programme
Núm. expedient: CAIXA-IMPULSE/CI23-20514
- **DECIPHERING AND PROMOTING ADAPTIVE IMMUNITY SPECIFIC TO POLYOMAVIRUS (BKV) TO PREVENT BKV INFECTION IN KIDNEY TRANSPLANTATION (BK-VAX PROJECT)**
Investigadores Principales: Bestard Matamoros, Oriol; Crespo Gimeno, Elena
Col-laboradores: Torija, Alba; Donadeu, Laura; Esperalba, Juliana, Sellares, Joana.
Entitat finançadora: Instituto de Salud Carlos III
Núm. Expedient: PI22/01019
- **CARACTERIZACIÓN EN SANGRE PERIFÉRICA DE UNA FIRMA GÉNICA DE RECHAZO HUMORAL COMÚN EN TRASPLANTES DE ÓRGANOS SÓLIDOS**
Investigadors Principals: Meneghini, Maria Antonia
Col-laboradores: Torija, Alba; Donadeu, Laura; Sellares, Joana, Castells, Lluís, Muñoz, Marina; Quintero, Jesús; García, Elena; Cachero, Alba.
Entitat finançadora: Instituto de Salud Carlos III
Núm. Expedient: PI22/00749
- **MECANISMOS Y DIANAS TERAPEÚTICAS DE LA RESPUESTA INMUNOLÓGICA HUMORAL DE MEMORIA FACILITANDO EL RECHAZO DEL INJERTO EN EL TRASPLANTE RENAL (PROYECTO COMBAT)**
Investigador Principal: Bestard Matamoros, Oriol



Col·laboradores: Melilli, E.; Meneghini, Maria; Jarque, Marta; Torija, Alba; Gomà, Montse; Favà, Alex; De la Lama, Maria Eugenia

Entitat finançadora: Instituto de Salud Carlos III

Núm. Expedient: PI19/01710

- **EFFECTO DE UNA NUEVA ESTRATEGIA TERAPÉUTICA INMUNOSUPRESORA MEDIANTE EL BLOQUEO DUAL DE LAS SEÑALES DE CO-ESTIMULACIÓN A NIVEL DE CD28/CD80-CD86 Y PDL2/PD1 CON LA MOLÉCULA HYBRI-2 PARA INHIBIR LA RESPUESTA DE MEMORIA HUMORAL Y DAR ACCESO AL TRASPLANTE EN PACIENTES ALTAMENTE SENSIBILIZADOS**

Investigador Principal: Bestard Matamoros, Oriol

Col·laboradores: Crespo Gimeno, Elena; Meneghini, Maria; Bolaños, Núria; Torija, Alba; Grinyó Boira, Josep Maria

Entitat finançadora: Fundación Renal Iñigo Alvarez de Toledo (FRIAT)

Núm. Expedient: Proyectos de Aplicación Práctica en Nefrología 2019

- **DECIPHERING THE MECHANISMS OF PLA2R-SPECIFIC B-CELL AUTOIMMUNITY IN PRIMARY MEMBRANOUS NEPHROPATHY (PMN) (BCELL-MEM) (projecto coordinado Hospital Universitari de Bellvitge -HUB y Hospital Universitari Vall d'Hebron- HUVH)**

Investigadores Principales: Torras Ambros, Joan (HUB) – Soler, M^a José (HUVH)

Colaboradores: Bestard Matamoros, Oriol; Bordignon Draibe, Juliana; Fulladosa Oliveras, Xavier; Martinez Valenzuela, Laura; Crespo Gimeno, Elena; Torija Recasens, Alba; Serón Micas, Daniel; Agraz Pamplona, Irene; García Carro, Clara; Jacobs Cacha, Conxita, Gabaldón Domínguez, Maria Alejandra

Entidad financiadora: Fundació La Marató TV3

Núm. expedient: 202037-30-31 421/C/2020

- **HORUS, Casting light on HOSt-cytomegalovirus interaction in Solid organ transplantation**

Investigador Principal: Bestard Matamoros, Oriol

Entitat finançadora: European Commission

Núm. Expedient: 101057651

- **AGORA, Algorithm of graft outcome in renal allograft transplantation.**

Investigador Principal: Bestard Matamoros, Oriol.

Entitat finançadora: European Commission (ERAP PerMed) & ISCIII.

Núm. Expedient: AC21_2/00050

- **BIOIMMUN: Estudi multicèntric, aleatoritzat per avaluar l'eficàcia de la individualització del risc immunològic basat en biomarcadors selectius (disparitat d'eplets HLA ELISPOT IFN- γ), per optimitzar el tractament immunosupressor en pacients trasplantats renals de donant viu.** Generalitat de Catalunya. Departament de Sanitat. SLT002/16/00183. 2017-2019. Principal Investigator: Oriol Bestard

